A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

NCT07154745 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: Pozelimab
DRUG: Cemdisiran

Sponsor

Regeneron Pharmaceuticals